Corcept Therapeutics Inc (CORT)

HEALTH CARE: BIOTECHNOLOGY & LIFE SCIENCES
SIC: PHARMACEUTICAL PREPARATIONS

149 COMMONWEALTH DRIVE MENLO PARK, CA 94025

Develops medications for the treatment of severe psychiatric and neurological diseases. Since its inception in 1998, this development stage company (May 13, 2005) has been developing its lead product, CORLUX, targeted for the treatment of the psychotic features of psychotic major depression.

Data as of 2020-08-01
Market Cap1.713 Billion Shares Outstanding114.602 Million Avg 30-day Volume964.284 Thousand
P/E Ratio18.3 Dividend Yield EPS0.88
Price/Sales6.523 Price cash flow ratio13.5 Price free cash flow ratio15.4
Book Value3.57 Price to Tangible Book4.5 Alpha0.02
Short Interest Ratio % Short Interest to Float R-squared0.08904
BETA1.07356 52-week High/Low18.525 / 9.7 Stddev0.154794
View SEC Filings from CORT instead.
Q1 2020 All Institutions Hedge Funds 1
Filers who had this stock in their top 10: 2 2 (0.13%)
13F Filers holding this stock: 200 60 (3.93%)
Aggregate 13F shares on 03/31/2020: 87.056 Million 42.568 Million
Aggregate 13F shares on 12/31/2019: 89.068 Million 40.244 Million
Percent change: -2.26% 5.77%
Funds creating new positions: 37 14
Funds Adding to an existing position: 72 23
Funds closing out their position: 35 18
Funds reducing their position: 59 19
1 hedge funds as identified by whalewisdom.com through public filings.

View recent insider trading info

Funds Holding CORT (via 13F filings)

Refresh Download CSV Download Excel (.xlsx) Download TSV
Filter by:
to
to
to
Refresh
*Shares are split adjusted
*Please note that if a filer hasn't submitted a 13F filing for a quarter then the filer's shares will be listed as "Sold All"

Mutual Funds Holding CORT BETA

Active Schedule 13D and 13G filings

Please sign in first

Open Market Buys/Sells Last 60 Days

Open Market Buys (P)

none

Open Market Sells (S)

5 Thousand total shares from 1 transactions

Exercise Derivative Conversion (M)

5 Thousand total shares from 1 transactions

Current/Former Insiders

Insider Name Type Last Reported Shares Held Last Reported Date Filings in past year

BRADBURY DANIEL

  • Director
863,578 2020-07-21 0

SWISHER DANIEL N JR

  • Director
0 2020-07-17 3

MADUCK SEAN CHIEF COMMERCIAL OFFICER

  • Officer
0 2020-07-13 2

LYON JOSEPH DOUGLAS CHIEF ACCOUNTING OFFICER

  • Officer
0 2020-07-13 2

HUNT HAZEL CHIEF SCIENTIFIC OFFICER

  • Officer
200 2020-07-13 2

WILSON JAMES N

  • Director
2,466,429 2020-07-10 4

BIRD JEFFREY W

  • Director
0 2020-07-02 0

SANDS GREGORY P

  • Director
542,662 2020-06-30 0

ENRIGHT PATRICK G

0 2020-06-30 0

LO STEVEN CHIEF EXECUTIVE OFFICER

146,250 2020-06-25 0

WHITE JAMES N

  • Director
525,724 2020-06-17 0

GALA RENEE D

  • Director
0 2020-06-17 0

COXE TENCH

  • Director
1,217,937 2020-06-10 0

SHEEHAN ANDREW T

  • Director
1,794,324 2020-06-09 0

MAHONEY DAVID L

  • Director
64,781 2020-06-03 2

LOEWY CAROLINE M

  • Director
0 2020-06-03 0

BAKER G LEONARD JR

  • Director
5,066,686 2020-05-27 2

PARK KIMBERLY

  • Director
0 2020-05-27 3

ALTON GREGG H

  • Director
0 2020-05-27 3

TURNER JOSEPH L

  • Director
0 2020-05-21 0

GAITHER JAMES C

  • Director
88,301 2020-03-31 0

BELANOFF JOSEPH K CHIEF EXECUTIVE OFFICER

  • Officer
  • Director
2,499,214 2020-02-26 2

TAMMENOMS BAKKER JULIET

  • FORMER DIRECTOR
0 2020-02-14 0

ROBB GARY CHARLES CHIEF FINANCIAL OFFICER

  • Officer
0 2020-02-07 3

GRAUER ANDREAS CHIEF MEDICAL OFFICER

  • Officer
0 2020-02-07 1

SPEISER MICHAEL L

  • Director
130,319 2019-06-20 0

PENHOET EDWARD

  • Director
0 2019-04-02 0

FISHMAN ROBERT S CHIEF MEDICAL OFFICER

  • Officer
0 2018-11-07 0

PULLARA SAMUEL J III

  • FORMER 10% HOLDER
No longer subject to file 2018-07-02 0

DYCKERHOFF STEFAN A

  • FORMER 10% HOLDER
No longer subject to file 2018-07-02 0

SUTTER HILL VENTURES

  • FORMER 10% HOLDER
No longer subject to file 2018-07-02 0

YOUNGER WILLIAM H JR

  • FORMER DIRECTOR
No longer subject to file 2017-06-30 0

LONGITUDE VENTURE PARTNERS L.P.

LONGITUDE CAPITAL PARTNERS, LLC

TAMMENOMS BAKKER JULIET

LONGITUDE CAPITAL ASSOCIATES, L.P.

  • 10% Owner
No longer subject to file 2016-11-28 0

LEDOUX ANNE M VP & CONTROLLER

  • Officer
50,000 2015-09-28 0

COOK JOSEPH C JR

  • Director
0 2015-06-18 0

SWEET DAVID E

  • 10% Owner
4,766,505 2014-10-01 0

ANDERSON DAVID L

  • 10% Owner
4,846,437 2014-10-01 0

HARPER JAMES A

  • Director
No longer subject to file 2014-02-03 0

ROE ROBERT L PRESIDENT AND SECRETARY

  • Officer
0 2013-01-30 0

SUTTER HILL VENTURES

WHITE JAMES N

  • 10% Owner
5,316,967 2012-03-29 0

SUTTER HILL VENTURES

BAKER G LEONARD JR

ANDERSON DAVID L

YOUNGER WILLIAM H JR

COXE TENCH

GAITHER JAMES C

SWEET DAVID E

SHEEHAN ANDREW T

SPEISER MICHAEL L

BIRD JEFFREY W

  • Director
  • 10% Owner
5,316,967 2012-03-29 0

SUTTER HILL VENTURES

BIRD JEFFREY W

WHITE JAMES N

  • 10% Owner
5,036,602 2011-10-21 0

SUTTER HILL VENTURES

BAKER G LEONARD JR

ANDERSON DAVID L

YOUNGER WILLIAM H JR

COXE TENCH

SANDS GREGORY P

GAITHER JAMES C

SWEET DAVID E

SHEEHAN ANDREW T

SPEISER MICHAEL L

  • Director
  • 10% Owner
5,036,602 2011-10-21 0

ALTA BIOPHARMA PARTNERS II LP

ALTA BIOPHARMA MANAGEMENT II LLC

ALTA EMBARCADERO BIOPHARMA PARTNERS II LLC

ALTA PARTNERS II INC

DELEAGE JEAN

CHAMPSI FARAH

  • 10% Owner
5,664,267 2009-10-16 0

PAPERBOY VENTURES, LLC

  • Director
209,694 2009-05-07 0

ANDERSSON ALLEN

  • Director
306,837 2009-05-07 0

ALTA BIOPHARMA PARTNERS II LP

MARDUEL ALIX

DELEAGE JEAN

CHAMPSI FARAH

ALTA BIOPHARMA MANAGEMENT II LLC

ALTA EMBARCADERO BIOPHARMA PARTNERS II LLC

ALTA PARTNERS II INC

  • 10% Owner
5,314,616 2008-11-11 0

ALTA BIOPHARMA PARTNERS II LP

ALTA CALIFORNIA MANAGEMENT PARTNERS II LLC

ALTA EMBARCADERO PARTNERS II LLC

DELEAGE JEAN

CHAMPSI FARAH

ALTA PARTNERS II INC

  • 10% Owner
5,209,790 2008-03-25 0

MARDUEL ALIX

  • Director
  • 10% Owner
5,209,790 2008-03-25 0

Insider Transactions Last 60 Days

Reporting Owners Transaction Date Transaction Code Shares Share Price Acquired or Disposed Shares Owned Following Transaction Combined shares owned after filing Direct/Indirect Ownership 10b-5

SWISHER DANIEL N JR - Director

2020-07-17 S 5,000 $16.48 d 0 0.00 direct yes

SWISHER DANIEL N JR - Director

2020-07-17 M 5,000 $6.55 a 5,000 0.00 direct yes

SWISHER DANIEL N JR - Director

2020-07-17 M 5,000 d 60,000 0.00 direct yes

LYON JOSEPH DOUGLAS - Officer CHIEF ACCOUNTING OFFICER

2020-07-13 A 40,000 a 40,000 0.00 direct

MADUCK SEAN - Officer CHIEF COMMERCIAL OFFICER

2020-07-13 A 40,000 a 40,000 0.00 direct

HUNT HAZEL - Officer CHIEF SCIENTIFIC OFFICER

2020-07-13 A 40,000 a 40,000 0.00 direct

WILSON JAMES N - Director james n. wilson and pamela d. wilson trust

2020-07-10 G 12,500 d 1,319,074 2,466,429.00 indirect
Transaction Code Definitions
Code Definition
A Grant, award or other acquisition pursuant to Rule 16b-3(d)
C Conversion of derivative security
D Disposition to the issuer of issuer equity securities pursuant to Rule 16b-3(e)
E Expiration of short derivative position
F Payment of exercise price or tax liability by delivering or withholding securities incident to the receipt, exercise or vesting of a security issued in accordance with Rule 16b-3
G Bona fide gift
H Expiration (or cancellation) of long derivative position with value received
I Discretionary transaction in accordance with Rule 16b-3(f) resulting in acquisition or disposition of issuer securities
J Other acquisition or disposition
L Small acquisition under Rule 16a-6
M Exercise or conversion of derivative security exempted pursuant to Rule 16b-3
O Exercise of out-of-the-money derivative security
P Open market or private purchase of non-derivative or derivative security
S Open market or private sale of non-derivative or derivative security
U Disposition pursuant to a tender of shares in a change of control transaction
W Acquisition or disposition by will or the laws of descent and distribution
X Exercise of in-the-money or at-the-money derivative security
Z Deposit into or withdrawal from voting trust

Elevate your investments